Madison, N.J.-based Quest won an early termination of the premerger review from the FTC, bringing the company another step closer to acquiring the Worcester, Mass.-based laboratory, which specializes in genetic testing for neurological disorders.
Athena makes diagnostic tests used to rule out, or confirm, physicians’ diagnoses of neurological conditions, such as Alzheimer’s disease, neuromuscular disorders, such as Spinal Muscular Atrophy, in addition to developmental disorders. The company’s tests offering and intellectual property portfolio includes more than 350 diagnostic tests, according to Quest.
Quest, which earlier this month announced plans to buy genomics firm Celera Corp. (NSDQ:CRA) for $671 million, is in the process raising $1.25 billion from senior unsecured notes to finance the Athena buyout.
Here’s a roundup of companies announcing mergers, acquisitions and divestitures.
- Frazier Healthcare affiliates close buyout of CareFusion OnSite instrument management biz
CareFusion (NYSE:CFN) and Frazier Healthcare today announced they have completed the exchange of CareFusion’s OnSite Services instrument management and repair business to affiliates of Frazier Healthcare.
- CryoLife signs agreement to acquire Cardiogenesis for $22 million
CryoLife Inc. (NYSE:CRY), an implantable biological medical device and cardiovascular tissue processing company, and Cardiogenesis Corp. (OTC:CGCP), a developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, announced that the boards of directors of both companies approved a definitive agreement under which CryoLife will acquire all of the outstanding shares of Cardiogenesis for $0.457 per share.
- GTCR closes acquisition of Sterigenics
GTCR, a private equity firm, announced it has completed the acquisition of Sterigenics International Inc., a global provider of contract sterilization and ionization services for medical devices, food products, and advanced applications, from Silverfleet Capital and PPM America Capital Partners.
- Biotectix buys assets from Chameleon BioSurfaces
Biotectix, LLC announced today the acquisition of all significant assets owned by Chameleon BioSurfaces Ltd. (Cambridge, United Kingdom). Financial terms were not disclosed. Chameleon has been a leading developer of advanced polymer coatings for implantable medical devices.
- Ecron Acunova acquires majority stake in aCROnordic
Ecron Acunova (EA), a full-service expert CRO with well-directed multi-continental spread, announced acquisition of majority stake of aCROnordic, a CRO specialised in clinical research in Nordic countries. aCROnordic is a full service CRO covering Denmark, Sweden, Finland and Norway.
- Health Evolution Partners announces sale of CambridgeSoft to PerkinElmer
Health Evolution Partners, a manager of healthcare investment funds, announced today that its portfolio company, CambridgeSoft, has entered into a definitive agreement to be acquired by PerkinElmer Inc (NYSE:PKI). CambridgeSoft is a developer of discovery, collaboration and research management software for the pharmaceutical industry.
- Neuro-Biotech Corp. completes due diligence on AURIC offer
Neuro-Biotech Corp. (OTC:MRES) announces that management has completed its due diligence process. Following the completion of the preliminary due diligence, Neuro-Biotech Corp. Has come to the conclusion that it is in the best interest of the company not to proceed in pursuing any longer those negotiations in regards to the unsolicited offer from AURIC Pharma Science at the present time. Following a careful review of the documents that where provided by AURIC, the company has not been able to get satisfactory answer and information in order to complete the basic due diligence procedure as was initially agreed on.